Cellectar Biosciences will announce its financial results for Q2 ending June 30, 2026, and provide a corporate update on August 13, 2026. The company focuses on developing targeted cancer treatments using its proprietary drug delivery platform. Key products include iopofosine I 131, in Phase 2b trials for various cancers, and CLR 125, in Phase 1b trials for solid tumors. The update will likely cover progress in clinical trials and regulatory designations that support the company’s growth prospects.
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.58% stake in Gamma Communications PLC as of July 29, 2026. The disclosure, made under Rule 8.3 of the Takeover Code, indicates ownership of 1,414,785 ordinary shares. This filing is a ...
Therma Bright Inc. has issued 6,613,999 common shares at $0.06 each to settle $396,840 in debt, including 4,699,999 shares to directors and officers. CEO Rob Fia received 4,349,999 shares, increasing his ownership from about 7% to 13.1% of the compan...
Sprott Inc. announced it will release its financial results for the second quarter of 2026 on August 5 at 7:00 a.m. ET. The company will host a webcast at 10:00 a.m. ET the same day, featuring CEO Whitney George, CFO Kevin Hibbert, and Asset Manageme...
